Compare STRIDES PHARMA SCIENCE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs TORRENT PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE TORRENT PHARMA STRIDES PHARMA SCIENCE/
TORRENT PHARMA
 
P/E (TTM) x 16.2 38.5 42.0% View Chart
P/BV x 1.0 8.4 11.9% View Chart
Dividend Yield % 0.5 0.7 67.2%  

Financials

 STRIDES PHARMA SCIENCE   TORRENT PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
TORRENT PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1471,964 58.4%   
Low Rs6421,245 51.6%   
Sales per share (Unadj.) Rs317.2453.4 70.0%  
Earnings per share (Unadj.) Rs7.825.8 30.4%  
Cash flow per share (Unadj.) Rs25.162.3 40.2%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.21.1 21.1%  
Book value per share (Unadj.) Rs274.3279.2 98.2%  
Shares outstanding (eoy) m89.50169.22 52.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.5 79.7%   
Avg P/E ratio x114.062.2 183.2%  
P/CF ratio (eoy) x35.725.8 138.6%  
Price / Book Value ratio x3.35.7 56.8%  
Dividend payout %25.565.9 38.7%   
Avg Mkt Cap Rs m80,058271,513 29.5%   
No. of employees `0002.513.6 18.4%   
Total wages/salary Rs m4,34114,038 30.9%   
Avg. sales/employee Rs Th11,325.85,642.6 200.7%   
Avg. wages/employee Rs Th1,731.41,032.4 167.7%   
Avg. net profit/employee Rs Th280.1320.9 87.3%   
INCOME DATA
Net Sales Rs m28,39476,728 37.0%  
Other income Rs m941571 164.9%   
Total revenues Rs m29,33477,299 37.9%   
Gross profit Rs m3,96519,831 20.0%  
Depreciation Rs m1,5406,177 24.9%   
Interest Rs m1,9625,038 39.0%   
Profit before tax Rs m1,4039,187 15.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-3,570 12.2%   
Tax Rs m971,254 7.8%   
Profit after tax Rs m7024,363 16.1%  
Gross profit margin %14.025.8 54.0%  
Effective tax rate %6.913.6 50.8%   
Net profit margin %2.55.7 43.5%  
BALANCE SHEET DATA
Current assets Rs m24,83650,375 49.3%   
Current liabilities Rs m18,99351,653 36.8%   
Net working cap to sales %20.6-1.7 -1,235.7%  
Current ratio x1.31.0 134.1%  
Inventory Days Days7192 77.1%  
Debtors Days Days11368 166.0%  
Net fixed assets Rs m34,28983,648 41.0%   
Share capital Rs m895846 105.8%   
"Free" reserves Rs m23,65146,397 51.0%   
Net worth Rs m24,54647,244 52.0%   
Long term debt Rs m15,51339,129 39.6%   
Total assets Rs m65,437141,209 46.3%  
Interest coverage x1.72.8 60.7%   
Debt to equity ratio x0.60.8 76.3%  
Sales to assets ratio x0.40.5 79.9%   
Return on assets %4.16.7 61.2%  
Return on equity %2.99.2 31.0%  
Return on capital %6.912.3 55.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69722,103 71.0%   
Fx outflow Rs m7355,522 13.3%   
Net fx Rs m14,96216,581 90.2%   
CASH FLOW
From Operations Rs m1,87117,981 10.4%  
From Investments Rs m5,826-2,413 -241.5%  
From Financial Activity Rs m-10,157-13,145 77.3%  
Net Cashflow Rs m-2,6152,380 -109.9%  

Share Holding

Indian Promoters % 27.7 71.5 38.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 7.0 538.5%  
FIIs % 8.6 12.6 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.8 294.3%  
Shareholders   56,241 26,511 212.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 187 Points Higher(Closing)

Indian share markets end on a positive note with the Sensex up by 187 points, while the Nifty closed up by 36 points.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 7, 2020 03:35 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - DIVIS LABORATORIES COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS